ArticleClinical genitourinary cancer2023
Response and Outcomes of Maintenance Avelumab After Platinum-Based Chemotherapy (PBC) in Patients With Advanced Urothelial Carcinoma (aUC): "Real World" Experience.
Open access · greenAbstract read
In one paragraph
Article in Clinical genitourinary cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
8.6field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 27 citations in OpenAlex.
- Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Real-World Results From an Early Access Program in Malaysia.Asia-Pacific journal of clinical oncology · 2026Article
- Article
- Oncological Outcomes and Prognostic Factors of Platinum-Based Chemotherapy Followed by Avelumab Maintenance Therapy Compared With Platinum-Based Chemotherapy Alone: A Propensity Score-Matched Analysis in a Real-World Population.International journal of urology : official journal of the Japanese Urological Association · 2026Article
- Outcomes with Avelumab Maintenance Treatment for Advanced Urothelial Cancer in a US Patient Cohort.Current oncology (Toronto, Ont.) · 2026Article
- Avelumab maintenance in advanced urothelial carcinoma: real-world data from Northern Spain (AVEBLADDER study).Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025Article
- JAVEMACS-D: claims database analysis of avelumab maintenance therapy for advanced urothelial carcinoma in Japan.Scientific reports · 2025Observational
- Article
- Real-World Outcomes of Avelumab Maintenance Therapy in Patients With Curatively Unresectable Urothelial Carcinoma in Japan: Results From the Final Analysis of Postmarketing Surveillance.Cancer medicine · 2025Article
- A Podcast on Real-World Evidence with Avelumab First-Line Maintenance and Treatment Sequencing in Locally Advanced or Metastatic Urothelial Carcinoma.Targeted oncology · 2025Article
- Noninterventional retrospective study of standard-of-care systemic treatment patterns and outcomes in US patients with advanced urothelial carcinoma.The oncologist · 2025Article
- Real-World Retrospective Study of Clinical and Economic Outcomes Among Patients with Locally Advanced or Metastatic Urothelial Carcinoma Treated with First-Line Systemic Anti-Cancer Therapies in the United States: Results from the IMPACT UC-III Study.Current oncology (Toronto, Ont.) · 2025Article
- Maintenance Therapy With Avelumab for Patients With Metastatic Urothelial Carcinoma: A Real-World, Ambispective RAVE-Bladder Study.Cancer medicine · 2025Article
- READY: REAl-world Data from an Italian compassionate use program of avelumab first-line maintenance for locallY advanced or metastatic urothelial carcinoma.ESMO real world data and digital oncology · 2024Article
- A Podcast on Practical Considerations in Patients with Advanced Urothelial Cancer Receiving First-Line Cisplatin- or Carboplatin-Based Chemotherapy Followed by Avelumab Maintenance in a Changing Therapeutic Landscape.Advances in therapy · 2024Article
- J-AVENUE: A retrospective, real-world study evaluating patient characteristics and outcomes in patients with advanced urothelial carcinoma treated with avelumab first-line maintenance therapy in Japan.International journal of urology : official journal of the Japanese Urological Association · 2024Article
- Efficacy of avelumab maintenance therapy for advanced urothelial carcinoma with histologic subtype and divergent differentiation: a multicenter retrospective study conducted by the Uro-Oncology Group in Kyushu.Translational andrology and urology · 2024Article
- Avelumab first-line maintenance treatment in patients with locally advanced or metastatic urothelial carcinoma: real-world results from a Korean expanded access program.Frontiers in oncology · 2024Article
- Avelumab first-line maintenance treatment for advanced urothelial carcinoma: review of evidence to guide clinical practice.ESMO open · 2023Review
- Response and Outcomes of Maintenance Avelumab After Platinum-Based Chemotherapy (PBC) in Patients With Advanced Urothelial Carcinoma (aUC): "Real World" Experience.Clinical genitourinary cancer · 2023Article
- Survival and Safety Outcomes of Avelumab Maintenance Therapy for Advanced Urothelial Carcinoma from a Single-Center Experience.In vivo (Athens, Greece)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
35 authors at 20 institutions in 6 countries.
Dimitra Rafailia BakaloudiDivision of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA.
Rafee TalukderDivision of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA.
Genevieve Ihsiu LinDepartment of Epidemiology, University of Washington, Seattle, WA.
Dimitrios MakrakisDepartment of Medicine, Jacobi Medical Center-Albert Einstein College of Medicine, Bronx, NY.
Leonidas N DiamantopoulosDepartment of Medicine, University of Pittsburgh, Pittsburgh, PA.
Nishita TripathiDivision of Oncology, Department of Medicine, University of Utah, Salt Lake City, UT.
Neeraj AgarwalDivision of Oncology, Department of Medicine, University of Utah, Salt Lake City, UT.
Roubini Zakopoulou2nd Propaedeutic Department of Internal Medicine, ATTIKON University Hospital, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece.
Aristotelis Bamias2nd Propaedeutic Department of Internal Medicine, ATTIKON University Hospital, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece.
Jason R BrownDivision of Oncology, University Hospitals Seidman Cancer Center, Clevelant, OH.
David J PinatoDepartment of Surgery and Cancer, Imperial College London, Hammersmith Campus, London, UK; Division of Oncology, Department of Translational Medicine (DIMET), University of Piemonte Orientale, Novara, Italy.
James KorolewiczDepartment of Surgery and Cancer, Imperial College London, Hammersmith Campus, London, UK.
Tanya JindalDivision of Hematology/Oncology, Department of Medicine, Helen Diller Family Cancer Center, University of California San Francisco, San Francisco, CA.
Vadim S KoshkinDivision of Hematology/Oncology, Department of Medicine, Helen Diller Family Cancer Center, University of California San Francisco, San Francisco, CA.
Jure MurgićDepartment of Oncology and Nuclear Medicine, University Hospital Center Sestre Milosrdnice, School of Dental Medicine, Zagreb, Croatia.
Marija MiletićDepartment of Oncology and Nuclear Medicine, University Hospital Center Sestre Milosrdnice, School of Dental Medicine, Zagreb, Croatia.
Ana FrobeDepartment of Oncology and Nuclear Medicine, Faculty of Dentistry, University Hospital Center Sestre Milosrdnice, Zagreb, Croatia.
Jeffrey JohnsonDivision of Oncology, Department of Medicine, University of Iowa, Iowa City, IA.
Yousef ZakhariaDivision of Oncology, Department of Medicine, University of Iowa, Iowa City, IA.
Alexandra DrakakiDivision of Hematology/Oncology, David Geffen School of Medicine at UCLA, Los Angeles, CA.
Alejo Rodriguez-VidaMedical Oncology Department, Hospital del Mar, IMM Research Institute, Barcelona, Spain.
Macarena Rey-CárdenasDepartment of Medical Oncology, Hospital Universitario 12 de Octubre, Madrid, Spain.
Daniel CastellanoDepartment of Medical Oncology, Hospital Universitario 12 de Octubre, Madrid, Spain.
Lucia Alonso BuznegoDepartment of Oncology, University Hospital Marqués of Valdecilla, IDIVAL Santander, Cantabria, Spain.
Ignacio DuranDepartment of Oncology, University Hospital Marqués of Valdecilla, IDIVAL Santander, Cantabria, Spain.
Clara Castro CarballeiraDepartment of Oncology, University Hospital Marqués of Valdecilla, IDIVAL Santander, Cantabria, Spain.
Rafael Morales BarreraDepartment of Medical Oncology, Vall d'Hebron Institute of Oncology, Vall d' Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain.
David MarmorejoDepartment of Medical Oncology, Vall d'Hebron Institute of Oncology, Vall d' Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain.
Rana R McKayMoores Cancer Center, University of California San Diego, La Jolla, CA.
Tyler StewartMoores Cancer Center, University of California San Diego, La Jolla, CA.
Shilpa GuptaDepartment of Hematology and Oncology, Taussig cancer Institute, Cleveland Clinic Foundation, Cleveland, OH.
Andrew Thomas RuplinDepartment of Pharmacy, Fred Hutchinson Cancer Center, Seattle, WA.
Evan Y YuDivision of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA.
Ali R KhakiDivision of Oncology, Department of Medicine, Stanford University, Palo Alto, CA. Electronic address: alikhaki@stanford.edu.
Petros GrivasDivision of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA. Electronic address: pgrivas@uw.edu.
University of Washington Medical Center · USMarqués de Valdecilla University Hospital · ESHospital Universitario 12 De Octubre · ESNational and Kapodistrian University of Athens · GRUniversitat Autònoma de Barcelona · ESUniversity Hospital Centre Zagreb · HRUniversity of California San Diego · USUniversity of California, San Francisco · USUniversity of Iowa · USUniversity of Utah · USCleveland Clinic · USFred Hutch Cancer Center · USHammersmith Hospital · GBHospital Del Mar · ESJacobi Medical Center · USStanford Medicine · USUniversità degli Studi del Piemonte Orientale “Amedeo Avogadro” · ITUniversity Hospitals Seidman Cancer Center · USUniversity of California, Los Angeles · USUniversity of Pittsburgh · US
Funding
TRAINING IN CANCER BIOLOGY &TRANSPLANTATIONT32CA009515 · NCI · UNIVERSITY OF WASHINGTON · PI NANCY ELLEN DAVIDSON, Effie W Petersdorf · 1985 to 2026
$16.2MContributing Factors and Consequences of Cancer Health DisparitiesT32CA094880 · NCI · UNIVERSITY OF WASHINGTON · PI Christopher I Li, AMANDA IRENE PHIPPS · 2017 to 2026
$3.7MNCI NIH HHS T32 CA009515NCI NIH HHS T32 CA094880Wellcome TrustWellcome Trust PS3416
Abstract
backgroundPlatinum-based chemotherapy (PBC) followed by avelumab switch maintenance in nonprogressors is standard first line (1L) treatment for advanced urothelial carcinoma (aUC). We describe clinical features and outcomes in a "real-world' cohort treated with avelumab maintenance for aUC. MATERIALS AND
methodsThis was a retrospective cohort study of patients (pts) who received 1L switch maintenance avelumab after no progression on PBC for aUC. We calculated progression-free survival (PFS) and overall survival (OS) from initiation of maintenance avelumab. We also described OS and PFS for specific subsets using Cox regression and observed response rate (ORR).
resultsA total of 108 pts with aUC from 14 sites treated with maintenance avelumab were included. There was a median of 6 weeks
conclusionsResults seem relatively consistent with findings from JAVELIN Bladder100 trial and recent "real world" studies. Prior response to platinum-based chemotherapy, ECOG PS 0, and absence of liver metastases were favorable prognostic factors. Limitations include the retrospective design, lack of randomization and central scan review, and possible selection/confounding biases.
Indexed as
Carcinoma, Transitional CellUrinary Bladder NeoplasmsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedHumansPlatinumRetrospective StudiesAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedavelumabPlatinumAnti-PD(L)1Bladder cancerImmune Checkpoint InhibitorsImmunotherapyUrinary tract cancer
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.